+28.6%
ROK vs GSK
+31.2%
-2.6%
-18.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.3% | -1.9% | +3.2% | +1.5% |
| 7D | +0.7% | -1.8% | +2.5% | +0.9% |
| 30D | -3.3% | -2.2% | -1.1% | -3.1% |
| 3M | -5.9% | -1.8% | -4.0% | -5.9% |
| 6M | +13.9% | -10.6% | +24.5% | +16.5% |
| YTD | +12.6% | +4.4% | +8.2% | +10.5% |
| 1Y | +28.6% | +30.4% | -1.8% | +20.7% |
| All | +28.6% | +31.2% | -2.6% | +20.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling